Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 441-452

  Nordquist, Lina ^a   Palm, Fredrik ^a,b   Andresen, Bradley T ^c,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c University of Missouri   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

C peptide; Diabetes mellitus; Insulin; Nephropathy; Signaling; Vascular

Indexed keywords

EID: 76749154007     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3221     Document Type: Article

References (110)

1. Al-Rasheed NM, Willars GB, Brunskill NJ. 2006. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol, 17:986-95.
2. Bab I, Gavish H, Namdar-Attar M, et al. 1999. Isolation of mitogenically active C-terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells. J Pept Res, 54:408-14.
3. Bain J, Plater L, Elliott M, et al. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J, 408:297-315.
4. Bank N, Aynedjian HS 1993. Role of EDRF nitric oxide in diabetic renal hyperfiltration. Kidney Int, 43:1306-12.
5. Bell TD, DiBona GF, Wang Y, et al. 2006. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol, 17:2184-92.
6. Blumer JB, Cismowski MJ, Sato M, et al. 2005. AGS proteins: receptorindependent activators of G-protein signaling. Trends Pharmacol Sci, 26:470-6.
7. Brown CD, Ghali HS, Zhao Z, et al. 2005. Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int, 67:295-300.
8. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813-20.
9. Chakrabarti S, Khan ZA, Cukiernik M, et al. 2004. C-peptide and retinal microangiopathy in diabetes. Exp Diabesity Res, 5:91-6.
10. Cifarelli V, Luppi P, Tse HM, et al. 2008. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-KB activation in vascular smooth muscle cells. Atherosclerosis, online first.
11. Crespo P, Xu N, Simonds WF, et al. 1994. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature, 369:418-20.
12. [DCCT] The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977-86.
13. De La Tour DD, Raccah D, Jannot MF, et al. 1998. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia, 41:1080-4.
14. Ditzel J, Standl E. 1975. The problem of tissue oxygenation in diabetes mellitus. Acta Med Scand Suppl, 578:59-68.
15. Escano CS, Keever LB, Gutweiler AA, et al. 2008. Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation. J Pharmacol Exp Ther, 324:34-42.
16. Fiorina P, Folli F, Zerbini G, et al. 2003a. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol, 14:2150-8.
17. Fiorina P, Folli F, Maffi P. 2003b. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidneyalone transplantation1. Transplantation, 75:1296-301.
18. Fiorina P, Gremizzi C, Maff P, et al. 2005a. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care, 28:1358-65.
19. Fiorina P, Venturini M, Folli F, et al. 2005b. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care, 28:1303-10.
20. Flatt PR., Swanston-Flatt SK, Hampton SM, et al. 1986. Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor. Biosci Rep, 6:193-9.
21. Forst T, Kunt T, Pohlmann T, et al. 1998. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest, 101:2036-41.
22. Gerthoffer WT, Yamboliev IA, Shearer M, et al. 1996. Activation of MAP kinases and phosphorylation of caldesmon in canine colonic smooth muscle. J Physiol, 495(Pt 3):597-609.
23. Grunberger G, Qiang X, Li Z, et al. 2001. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia, 44:1247-57.
24. Hansen A, Johansson BL, Wahren J, et al. 2002. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes, 51:3077-82.
25. Hauge C, Frodin M. 2006. RSK and MSK in MAP kinase signalling. J Cell Sci, 119(Pt 15):3021-3.
26. Hawes BE, Luttrell LM, van Biesen T, et al. 1996. Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem, 271:12133-6.
27. He H, Shehan BP, Barnham KJ, et al. 2004. Biological activity and ferric ion binding of fragments of glycine-extended gastrin. Biochemistry, 43:11853-61.
28. Hedin KE, Bell MP, Huntoon CJ, et al. 1999. Gi proteins use a novel beta gamma- and Ras-independent pathway to activate extracellular signal- regulated kinase and mobilize AP-1 transcription factors in Jurkat T lymphocytes. J Biol Chem, 274:19992-20001.
29. Henriksson M, Johansson J, Moede T, et al. 2006. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling. Cell Mol Life Sci, 63:3055-60.
30. Huang DY, Richter K, Breidenbach A, et al. 2002. Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study. Naunyn Schmiedebergs Arch Pharmacol, 365:67-73.
31. Huang J, Mahavadi S, Sriwai W, et al. 2006. Gi-coupled receptors mediate phosphorylation of CPI-17 and MLC20 via preferential activation of the PI3K/ILK pathway. Biochem J, 396:193-200.
32. Ido Y, Vindigni A, Chang K, et al. 1997. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science, 277:563-6.
33. Ikenaga H, Bast JP, Fallet RW, et al. 2000. Exaggerated impact of ATPsensitive K+ channels on afferent arteriolar diameter in diabetes mellitus. J Am Soc Nephrol, 11:1199-207.
34. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, et al. 1989. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 18636:461-3.
35. Johansson BL, Linde B, Wahren J. 1992a. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 insulin-dependent diabetic patients. Diabetologia, 3512:1151-8.
36. Johansson BL, Sjoberg S, Wahren J. 1992b. The influence of human C-peptide on renal function and glucose utilization in type 1 insulindependent diabetic patients. Diabetologia, 352:121-8.
37. Johansson BL, Borg K, Fernqvist-Forbes E, et al. 2000. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med, 173:181-9.
38. Johansson BL, Wahren J, Pernow J. 2003. C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab, 2854:E864-70.
39. Juncos L A, Ito S. 1993. Disparate effects of insulin on isolated rabbit afferent and efferent arterioles. J Clin Invest, 924:1981-5.
40. Kalantarinia K, Awad AS, Siragy HM. 2003. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int, 644:1208-13.
41. Kamikawa A, Ishii T, Shimada K, et al. 2008. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev, 24:331-8.
42. Katada T, Ui M. 1982. ADP ribosylation of the specific membrane protein of C6 cells by islet-activating protein associated with modification of adenylate cyclase activity. J Biol Chem, 25712:7210-16.
43. Katz A, Wu D, Simon MI. 1992. Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C. Nature, 3606405:686-9.
44. Kimura K, Ito M, Amano M, et al. 1996. Regulation of myosin phosphatase by Rho and Rho-associated kinase Rho-kinase. Science, 2735272:245-8.
45. Kitamura T, Kimura K, Jung BD, et al. 2001. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J, 355(Pt 1):123-9.
46. Kitamura T, Kimura K, Jung BD, et al. 2002. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogenactivated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J, 366(Pt 3):737-44.
47. Kitamura T, Kimura K, Makondo K, et al. 2003. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein- kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia, 4612:1698-705.
48. Kitazawa M, Shibata Y, Hashimoto S, et al. 2006. Proinsulin C-peptide stimulatesa PKC/IkappaB/NF-kappaB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts. J Biochem, 1396:1083-8.
49. Klee CB, Crouch TH, Krinks MH. 1979. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci USA, 7612:6270-3.
50. Kobayashi Y, Naruse K, Hamada Y, et al. 2005. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in highglucose conditions. Diabetologia, 4811:2396-401.
51. Koch WJ, Hawes BE, Allen LF, et al. 1994. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. Proc Natl Acad Sci USA, 9126:12706-10.
52. Komers R, Allen TJ, Cooper ME. 1994. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes, 4310:1190-7.
53. Kunt T, Schneider S, Pfutzner A, et al. 1999. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia, 424:465-71.
54. L'Allemain G, Pouyssegur J, Weber MJ. 1991. p42/mitogen-activated protein kinase as a converging target for different growth factor signaling pathways: use of pertussis toxin as a discrimination factor. Cell Regul, 28:675-84.
55. Lea JP, Sands JM, McMahon SJ. 1994. Evidence that the inhibition of Na+/K+-ATPase activity by FK506 involves calcineurin. Kidney Int, 463:647-52.
56. Lee JC, Downing SE 1979. Coronary dynamics and myocardial metabolism in the diabetic newborn lamb. Am J Physiol, 2372:H118-24.
57. Lee TC, Barshes NR, Agee EE, et al. 2006. The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr Diab Rep, 64:323-7.
58. Li H, Xu L, Dunbar JC, et al. 2004. Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. Urology, 643:622-7.
59. Li ZG, Zhang L, Sima AA. 2003. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev, 195:375-85.
60. Lindahl E, Nyman U, Melles E, et al. 2007. Cellular internalization of proinsulin C-peptide. Cell Mol Life Sci, 644:479-86.
61. Lindstrom K, Johansson C, Johnsson E, et al. 1996. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. Acta Physiol Scand, 1561:19-25.
62. Lopez-Ilasaca M, Crespo P, Pellici PG, et al. 1997. Linkage of G proteincoupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science, 2755298:394-7.
63. Luttrell LM, Hawes BE, van Biesen BE, et al. 1996. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunitmediated activation of mitogen-activated protein kinases. J Biol Chem, 27132:19443-50.
64. Maezawa Y, Yokote K, Sonezaki K, et al. 2006. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev, 224:313-22.
65. Mashimo H, Goyal RK. 1999. Lessons from genetically engineered animal models. IV. Nitric oxide synthase gene knockout mice. Am J Physiol, 2774(Pt 1):G745-50.
66. Meyer JA, Froelich JM, Reid GE, et al. 2008. Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter. Diabetologia, 51:175-82.
67. Moriwaki Y, Inokuchi T, Yamamoto A, et al. 2007. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol, 444:215-18.
68. Nordquist L, Moe E, Sjoquist M. 2007. The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev, 23:400-405.
69. Nordquist L, Lai EY, Sjoquist M, et al. 2008a. Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism. Am J Physiol Regul Integr Comp Physiol, 294:R836-41.
70. Nordquist L, Lai EY, Sjoquist M, et al. 2008b. C-peptide constricts pancreatic islet arterioles in diabetic, but not normoglycaemic mice. Diabetes Metab Res Rev, 24:165-8.
71. Ohtomo Y, Aperia A, Sahlgren B, et al. 1996. C-peptide stimulates rat renal tubular Na+, K+-ATPase activity in synergism with neuropeptide Y. Diabetologia, 392:199-205.
72. Ohtomo Y, Bergman T, Johansson BL, et al. 1998. Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity of renal tubule segments. Diabetologia, 413:287-91.
73. Portelli M, Renzi G. 1973. Pentapeptide derivatives of the C-terminal tetrapeptide of gastrin. Farmaco Sci, 284:316-22.
74. Raccah D, Fabreguetts C, Azulay JP, et al. 1996. Erythrocyte Na+-K+- ATPase activity, metabolic control, and neuropathy in IDDM patients. Diabetes Care, 196:564-8.
75. Ramasharma K, Yamashiro D, Li CH. 1988. Human follicular gonadotropin releasing peptide analogs. Evaluation of biological in vitro and immunological activity. Int J Pept Protein Res, 326:419-24.
76. Rebsomen L, Tsimaratos M 2005. Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int, 675:2066; author reply 2066-7.
77. Rigler R, Pramanik A, Jonasson P, et al. 1999. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA, 9623:13318-23.
78. Roberts RE. 2004. The role of Rho kinase and extracellular regulated kinasemitogen- activated protein kinase in alpha2-adrenoceptor-mediated vasoconstriction in the porcine palmar lateral vein. J Pharmacol Exp Ther, 311:742-7.
79. Roos MH, van Rodijnen WF, van Lambalgen AA, et al. 2006. Renal microvascular constriction to membrane depolarization and other stimuli: pivotal role for rho-kinase. Pflugers Arch, 452:471-7.
80. Sakai H, Chiba Y, Misawa M. 2007. Role of Rho kinase in endothelin-1- induced phosphorylation of CPI-17 in rat bronchial smooth muscle. Pulm Pharmacol Ther, 20:734-9.
81. Sallstrom J, Carlsson PO, Fredholm BB, et al. 2007. Diabetes-induced hyperfiltration in adenosine A1-receptor deficient mice lacking the tubuloglomerular feedback mechanism. Acta Physiol Oxf, 190:253-9.
82. Samnegard B, Brundin T. 2001. Renal extraction of insulin and C-peptide in man before and after a glucose meal. Clin Physiol, 21:164-71.
83. Samnegard B, Jacobson SH, Jaremko G, et al. 2001. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int, 60:1258-65.
84. Samnegard B, Jacobson SH, Johansson BL, et al. 2004. C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant, 19:1385-91.
85. Samnegard B, Jacobson SH, Jaremko G, et al. 2005. C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant, 20:532-8.
86. Sandow J, Konig W. 1979. Studies with fragments of a highly active analogue of luteinizing hormone releasing hormone. J Endocrinol, 81:175-82.
87. Sari R, Balci MK. 2005. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc, 97:1113-18.
88. Schmidt C, Hocherl K, Schweda F, et al. 2007. Regulation of renal glucose transporters during severe inflammation. Am J Physiol Renal Physiol, 292:F804-11.
89. Schonwasser DC, Marais RM, Marshall CJ, et al. 1998. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol, 18:790-8.
90. Sima AA, Li ZG. 2005. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes, 54:1497-505.
91. Sprague RS, Ellsworth ML, Stephenson LH, et al. 1996. ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol, 271(6Pt 2):H2717-22.
92. Sprague RS, Olearczyk JJ, Spence DM, et al. 2003. Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance. Am J Physiol Heart Circ Physiol, 285:H693-700.
93. Stoyanov B, Volinia S, Hanch T, et al. 1995. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science, 269:690-3.
94. Sutherland C, Leighton IA, Cohen P. 1993. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J, 296(Pt 1):15-19.
95. Thomson SC, Deng A, Bao D, et al. 2001. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest, 107:217-24.
96. Tsimaratos M, Roger F, Chabardes D, et al. 2003. C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia, 46:124-31.
97. Wakino S, Kanda T, Hayashi K. 2005. Rho/Rho kinase as a potential target for the treatment of renal disease. Drug News Perspect, 18:639-43.
98. Walcher D, Babiak C, Poletek P, et al. 2006. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res, 99:1181-7.
99. Wallerath T, Kunt T, Forst T, et al. 2003. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide, 9:95-102.
100. Vallon V, Blantz RC, Thomson S. 1995. Homeostatic efficiency of tubuloglomerular feedback is reduced in established diabetes mellitus in rats. Am J Physiol, 269(6Pt 2):F876-83.
101. Walsh MP, Susnjar M, Deng J, et al. 2007. Phosphorylation of the protein phosphatase type 1 inhibitor protein CPI-17 by protein kinase C. Methods Mol Biol, 365:209-23.
102. Wang YX, Brooks DP, Edwards RM. 1993. Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. Am J Physiol, 264(5Pt 2):R952-6.
103. Venturini M, Fiorina P, MaffiP, et al. 2006. Early increase of retinal arterial and venous blood flow velocities at color doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation, 81:1274-7.
104. West RE Jr, Moss J, Vaughan M, et al. 1985. Pertussis toxin-catalyzed ADPribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. J Biol Chem, 260:14428-30.
105. Viard P, Exner T, Maier U, et al. 1999. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. Faseb J, 13:685-94.
106. Wu D, Katz A, Simon MI. 1993. Activation of phospholipase C beta 2 by the alpha and beta gamma subunits of trimeric GTP-binding protein. Proc Natl Acad Sci U S A, 90:5297-301.
107. Yajima H, Kai Y, Ogawa H, et al. 1977. Structure-activity relationships of gastrointestinal hormones: motilin, GIP, and [27-TYR]CCK-PZ. Gastroenterology, 72(4Pt 2):793-6.
108. Young LH, Ikeda Y, Scalia R, et al. 2000. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol, 279:H1453-9.
109. Zhong Z, Kotova O, Davidescu A, et al. 2004. C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci, 61:2782-90.
110. Zhong Z, Davidescu A, Ehren I, et al. 2005. C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia, 48:187-97.